Acquisition by Baird William D Iii of 91000 shares of 2Seventy Bio subject to Rule 16b-3

TSVT Stock  USD 3.27  0.46  12.33%   
Slightly above 61% of 2Seventy Bio's investor base is looking to short. The analysis of the overall investor sentiment regarding 2Seventy Bio suggests that many traders are alarmed. 2Seventy Bio's investing sentiment can be driven by a variety of factors including economic data, 2Seventy Bio's earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by 2Seventy Bio Officer: Chief Operating Officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at simplywall.st
Simply Wall St News at Macroaxis
  
2Seventy insider trading alert for acquisition of common stock by Baird William D Iii, Officer: Chief Operating Officer, on 17th of August 2024. This event was filed by 2Seventy Bio with SEC on 2024-01-08. Statement of changes in beneficial ownership - SEC Form 4

2Seventy Bio Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards 2Seventy Bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

2Seventy Bio Fundamental Analysis

We analyze 2Seventy Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of 2Seventy Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of 2Seventy Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Profit Margin

Profit Margin Comparative Analysis

2Seventy Bio is currently under evaluation in profit margin category among its peers. Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.

2Seventy Bio Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with 2Seventy Bio stock to make a market-neutral strategy. Peer analysis of 2Seventy Bio could also be used in its relative valuation, which is a method of valuing 2Seventy Bio by comparing valuation metrics with similar companies.

Peers

2Seventy Bio Related Equities

KZRKezar Life   1.77   
0%
23.0%
PTGXProtagonist Therapeutics   1.51   
0%
20.0%
REPLReplimune   1.15   
0%
15.0%
INZYInozyme Pharma   0.67   
0%
9.0%
ASNDAscendis Pharma   0.07   
0%
1.0%
PHATPhathom Pharmaceuticals   0.38   
5.0%
0%
ZNTLZentalis Pharmaceuticals   0.96   
12.0%
0%
SNDXSyndax Pharmaceuticals   1.11   
15.0%
0%
CRNXCrinetics Pharmaceuticals   1.37   
18.0%
0%
SRPTSarepta Therapeutics   1.78   
24.0%
0%
STOKStoke Therapeutics   2.11   
28.0%
0%
CGEMCullinan Oncology   2.13   
28.0%
0%
PBYIPuma Biotechnology   2.40   
32.0%
0%
IOVAIovance Biotherapeutics   2.51   
33.0%
0%
DAWNDay One   2.89   
39.0%
0%
RLAYRelay Therapeutics   3.14   
42.0%
0%
RCUSArcus Biosciences   4.37   
59.0%
0%
PLRXPliant Therapeutics   4.69   
63.0%
0%
MRSNMersana Therapeutics   7.39   
100.0%
0%

Additional Tools for 2Seventy Stock Analysis

When running 2Seventy Bio's price analysis, check to measure 2Seventy Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 2Seventy Bio is operating at the current time. Most of 2Seventy Bio's value examination focuses on studying past and present price action to predict the probability of 2Seventy Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 2Seventy Bio's price. Additionally, you may evaluate how the addition of 2Seventy Bio to your portfolios can decrease your overall portfolio volatility.